Miami (May 13) – The Bronchiectasis and NTM Association has accepted one new Care Center and three new Clinical Associate Center sites into the Bronchiectasis and NTM Care Center Network (CCN). The CCN includes 62 centers across the United States.
The CCN aims to facilitate access to specialized care and support for the hundreds of thousands of people with bronchiectasis and nontuberculous mycobacterial (NTM) lung disease.
“People living with bronchiectasis and NTM lung disease deserve access to high-quality, specialized care and resources,” said Doreen Addrizzo-Harris, M.D., Chair of the CCN Steering Committee. “The CCN’s innovative network of expert centers is dedicated to enhancing care and improving quality of life for those living with these conditions.”
Centers accepted into the CCN receive a designation of either a Bronchiectasis and NTM Care Center or a Bronchiectasis and NTM Clinical Associate Center, based on institutional resources and infrastructure. The requirements are established by the CCN’s Steering Committee, comprised of leading experts in the field.
The new Bronchiectasis and NTM Care Center site is:
- UW Medicine, Seattle
The new Bronchiectasis and NTM Clinical Associate Center sites are:
- Atrium Health Wake Forest Baptist, Winston-Salem, N.C.
- Rutgers Robert Wood Johnson Medical School, New Brunswick, N.J.
- Renown Medical Group – Pulmonary Medicine, Reno, Nev.
The Bronchiectasis and NTM Care Center Network is generously supported by Insmed Incorporated as a Founding Sponsor and Boehringer Ingelheim.
For more information about the Bronchiectasis and NTM Care Center Network, visit www.bronchandntm.org.
###
About Bronchiectasis and NTM Lung Disease
Bronchiectasis is a chronic lung disease characterized by enlarged airways that are thickened and/or scarred. These permanently widened airways lead to a buildup of mucus and impaired clearance of bacteria from the lungs. Between 340,000 and 522,000 adults are receiving treatment in the U.S.
Nontuberculous mycobacterial (NTM) lung disease is a chronic respiratory condition caused by certain types of mycobacteria commonly found in the environment, such as in soil and water. NTM lung disease predominantly affects individuals with compromised immune systems or pre-existing lung conditions, such as bronchiectasis and chronic obstructive pulmonary disease (COPD). NTM lung disease affects tens of thousands of individuals in the U.S. with rates of infection on the rise.
About the Bronchiectasis and NTM Association
The Bronchiectasis and NTM Association is a nonprofit organization whose mission is to improve the lives of people with bronchiectasis, nontuberculous mycobacterial lung (NTM) disease, or both conditions. The Association accomplishes this by providing education, supporting advocacy, furthering research, and advancing high-quality, specialized care. For more information, visit www.bronchandntm.org.